Pharmaceutical Industry Reports Tourette Syndrome Treatment Market | Page 2

REPORT DESCRIPTION
Tourette Syndrome Treatment Market – Overview
Drug approvals by regulatory authorities is expected to boost the global tourette syndrome treatment market
growth. For instance, in October 23, 2017, Neurocrine Biosciences Inc. announced that the Food Drug and
Administration approved valbenazine orphan drug designation to treat the pediatric patients with the Tourette
syndrome. Furthermore, in September 19, 2017, Teva Pharmaceutical Industries and Nuvelution Pharma
announced their partnership to develop AUSTEDO (deutetrabenazine) tablets for the treatment of tics which is
associated to tourette syndrome in pediatric patients in the U.S. This partnership will drive the development of
Austedo (deutetrabenazine) in Tourette syndrome by bringing new treatment options more quickly which are more
necessary for the affected young patients. These factors are expected to propel the global Tourette syndrome
treatment market growth.
Moreover, there are several investigations made for the treatment of Tourette syndrome. For instance, in March
2019, Wesley Medical Research was partnering with the University of Sydney in Australia which carried the
clinical trial to investigate whether the medical cannabis could be used to treat the individuals with Tourette
syndrome. This trial will help examine efficacy and safety of cannabinoids on tic frequency as well as the
psychiatric symptoms associated with Tourette syndrome.